Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OLANZAPINE Cause Dermatitis exfoliative generalised? 9 Reports in FDA Database

Sharpen Your Memory & Focus Naturally

NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.

Boost Your Brain

According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Dermatitis exfoliative generalised have been filed in association with OLANZAPINE (Olanzapine). This represents 0.0% of all adverse event reports for OLANZAPINE.

9
Reports of Dermatitis exfoliative generalised with OLANZAPINE
0.0%
of all OLANZAPINE reports
1
Deaths
8
Hospitalizations

How Dangerous Is Dermatitis exfoliative generalised From OLANZAPINE?

Of the 9 reports, 1 (11.1%) resulted in death, 8 (88.9%) required hospitalization.

Is Dermatitis exfoliative generalised Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OLANZAPINE. However, 9 reports have been filed with the FAERS database.

What Other Side Effects Does OLANZAPINE Cause?

Drug ineffective (5,139) Weight increased (3,588) Off label use (3,256) Toxicity to various agents (3,175) Somnolence (2,612) Sedation (2,130) Suicide attempt (2,116) Confusional state (1,898) Condition aggravated (1,810) Overdose (1,765)

What Other Drugs Cause Dermatitis exfoliative generalised?

ALLOPURINOL (192) DUPILUMAB (162) METHOTREXATE (151) SULFAMETHOXAZOLE\TRIMETHOPRIM (140) AMOXICILLIN (122) ADALIMUMAB (113) PANTOPRAZOLE (105) SECUKINUMAB (96) VANCOMYCIN (92) AMLODIPINE (91)

Which OLANZAPINE Alternatives Have Lower Dermatitis exfoliative generalised Risk?

OLANZAPINE vs OLANZAPINE\SAMIDORPHAN L-MALATE OLANZAPINE vs OLAPARIB OLANZAPINE vs OLARATUMAB OLANZAPINE vs OLECLUMAB OLANZAPINE vs OLIVE OIL\SOYBEAN OIL

Related Pages

OLANZAPINE Full Profile All Dermatitis exfoliative generalised Reports All Drugs Causing Dermatitis exfoliative generalised OLANZAPINE Demographics